Skip to main content

Transmission Raman Spectroscopy for Pharmaceutical Analysis - Insights from Users and Regulators


Obtaining regulatory approval for QC batch release by transmission Raman: Bulk assay, uniformity and identification

  • Dr Julien Villaumié – R&D Senior Scientist, Actavis, UK

Obtaining Regulatory Approval for QC Batch Release by Transmission Raman: Bulk Assay, Uniformity and Identification

Obtaining Regulatory Approval for QC Batch Release by Transmission Raman: Bulk Assay, Uniformity and Identification

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

  • Dr Tom van den Kerkhof – Senior Scientist, Janssen, Belgium

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

  • Dr Gary McGeorge – Senior Principal Scientist, Bristol-Myers Squibb, USA

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

Examples of Transmission Raman Applications at GSK

  • Dr Benoît Igne – Principal Scientist, GSK, USA

Examples of Transmission Raman Applications at GSK

Examples of Transmission Raman Applications at GSK

Transmission Raman spectroscopy (TRS) is an alternative to HPLC for tablet & capsule content uniformity testing and polymorph quantification. Pharmaceutical manufacturers are increasingly using Cobalt's TRS system in R&D and production environments because of the benefits it offers: TRS takes seconds per sample, is robust to sample variation, needs no preparation, solvents or consumables and saves significant cost and resource per batch.

This seminar featured excellent and wide-ranging presentations from experienced TRS users at Bristol-Myers Squibb, Actavis, Janssen, GSK and AbbVie, with a regulatory perspective presented by the UK's MHRA. Many thanks to all our speakers for taking the time to travel and present their work. The event was very popular - we had more interest than spaces at the venue - and feedback suggests there is a high demand for more seminars in the future as the transmission Raman user community rapidly grows.

Obtaining regulatory approval for QC batch release by transmission Raman: Bulk assay, uniformity and identification

  • Dr Julien Villaumié – R&D Senior Scientist, Actavis, UK

Determination of crystallinity in amorphous solid dispersion-based pharmaceutical preparations by means of Transmission Raman-Spectrometry

  • Dr Holger Van Lishaut – Principal Research Scientist, AbbVie, Germany

A review of transmission Raman usage in pharmaceutical R&D at GSK

  • Dr Benoît Igne – Principal Scientist, GSK, USA

The development of transmission Raman spectroscopy for pharmaceutical analysis

  • Professor Pavel Matousek, STFC Senior Fellow & Cobalt Chief Scientific Officer, Rutherford Appleton Labs, UK

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

  • Dr Tom van den Kerkhof – Senior Scientist, Janssen, Belgium

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

  • Dr Gary McGeorge – Senior Principal Scientist, Bristol-Myers Squibb, USA

Improving your TRS methods: Beam Enhancers and other ideas

  • Dr Andrew Owen – Pharma Product Manager, Cobalt Light Systems, UK

The MHRA's expectations and experiences for spectroscopic methods

  • Dr Abigail Moran - Senior Pharmaceutical Assessor, Medical & Healthcare products Regulatory Agency (MHRA), UK

This event took place at St. Catherine's College, Oxford, on
Thursday December 3rd 2015


Quantitative analysis of intact tablets, capsules and powders

Quantitative analysis of intact tablets, capsules and powders